Class 1 new drugs independently developed by TUL enter clinical practice

Recently, Zhuhai United Laboratories Co., Ltd. received the "Notice of clinical trial" issued by the State Drug Administration, approving the company's class 1 innovative drug wxsh0150 tablets for clinical trial, with the acceptance number of [cxhl2000041; cxhl2000042; cxhl2000043].

Wxsh0150 is a small molecule tyrosine kinase (Jak1) selective inhibitor developed by Zhuhai United Laboratories Co., Ltd. with independent intellectual property rights. It is intended to treat moderate to severe active rheumatoid arthritis. JAK inhibitors block JAK kinase family, regulate JAK-STAT signaling pathway, block cytokine signal transduction, reduce the synthesis and secretion of inflammatory mediators, inhibit the occurrence and development of inflammation, so as to achieve the effect of relieving and treating rheumatoid arthritis.